X

What's new?

Search by Target is now Live!

The ability to search AdisInsight by Target is now available. This will be a new parameter on the Advanced Search page. Target is also available as a facet filter on the search results page.

AdisInsight Visualization is now Live!

AdisInsight visualization are analysis tools integrated into the AdisInsight internet platform and included in the subscription. It allows users to analyze key drug development parameters across the drugs in the their search results, use filter facets to modify graphs in real time, and export the graphs for use in presentation or off-line analysis. You can find the visualisation options available after running an initial search.

Improved Priority Status

We have improved reporting of priority drug status in AdisInsight. We added the Coronavirus Treatment Acceleration Program, which is the FDA special emergency program for possible coronavirus therapies. We also changed all abbreviations to full names following requests from our users.

Structure Search is Back

The functionality to search AdisInsight by chemical structure has returned. Users can once again draw or import small molecule structures and search for either complete or partial matches. This functionality was temporarily removed from the platform in February.

Improved Safety Email Alerts

We added a new section to our email alerts to communicate which AdisInsight Safety records have been updated. This section will include any Safety record that meets your email alert criteria and has been updated since your last alert delivery. The updated Safety report section will follow and compliment the section in the email that alerts you to new Safety reports published since your last alert delivery. This improvement was requested by a large number of our Safety users who needed a way to be alerted to both new and updated Safety reports.

More Up-to-Date Biomarker Information

We are excited to provide AdisInsight users with the most up-to-date insights into the biomarkers being used in drug development and clinical trials. In joint development with our biomarker content partner Amplion we have improved the timeliness of biomarker information in AdisInsight from what was roughly a quarterly update interval to what will ultimately be a daily update interval.

Quicker Search and Export

We have optimized our search and reduced latency between applications which has resulted in faster searching and less time waiting for exports to Excel and BizInt. This is especially true for complex or very broad queries which previously caused issues due to the length of time required to complete the task.

Download the new BizInt

Our friends at BizInt have added new fields including Targets to the AdisInsight edition of BizInt Smart Charts Lite. Visit http://www.bizint.com/product/adis to download the new version.

More Priority Status Added

You can now identify drug development programs with accelerated status including Regenerative Medicine Advanced Therapy (RMAT), Qualified Infectious Disease Product, and Breakthrough Therapy.

Drug Profile

Liraglutide depot

Alternative Names: Liraglutide once-weekly; Liraglutide-depot; NN 9223

Latest Information Update: 02 Oct 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Novo Nordisk
Class Anti-inflammatories; Antihyperglycaemics; Antiparkinsonians; Antirheumatics; Glucagon-like peptides; Obesity therapies
Mechanism of Action Glucagon-like peptide stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

Highest Development Phases

Discontinued Type 2 diabetes mellitus

Most Recent Events

21 Jun 2012 Discontinued - Phase-I for Type-2 diabetes mellitus in USA (SC)
31 Mar 2012 Novo Nordisk completes a phase I trial in Healthy volunteers in USA (NCT01473953)
31 Oct 2011 Phase-I clinical trials in Type-2 diabetes mellitus (in volunteers) in USA (SC)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Latest webinar now available!

Our latest webinar, Navigating the Complex Landscape of Clinical Trials: Trends, Global Impact, including Hits & Misses 2024, is available now. Key topics include an analysis of trials with both positive and negative outcomes, failed trials of 2024, and impactful trials of 2024 that contributed to regulatory approvals or company revenue, followed by an outlook on a few pivotal trials to watch in 2025.